Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents

  title={Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents},
  author={Whitney P. Caron and Gina Song and P. Kiran Kumar and Sumit Rawal and William C. Zamboni},
  journal={Clinical Pharmacology \& Therapeutics},
Major advances in the field of carrier‐mediated agents (CMAs) have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages over their small‐molecule counterparts (solubility, duration of exposure, and delivery to the site of action are higher), these agents display substantial variability in systemic clearance (CL) and distribution, tumor delivery, and pharmacologic effects. This review provides an overview of factors that affect the pharmacokinetics… 
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.
This review provides an overview of factors that affect the pharmacokinetics and pharmacodynamics of carrier-mediated agents in preclinical models and patients.
Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
An overview of tumor microenvironment factors that affect the pharmacokinetics and pharmacodynamics of carrier-mediated agents observed in preclinical models and patients are provided.
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents
An overview of factors that affect the pharmacologic profiles observed in CMA-formulated chemotherapy, primarily in liposomal formulations, that are currently in preclinical or early clinical development are provided.
Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.
Future studies are warranted to better understand the complex pharmacology and interaction of CMA carriers within individual preclinical models and their biological systems, such as the MPS and tumor microenvironment, and their application to allometric scaling across species.
Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.
This chapter focuses on the analytical and phenotypic methods required to design a study that characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of all forms of these nanoparticle-based drug agents.
Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems
This review aims to provide a summary of fundamental factors that affect the disposition of NPs in the treatment of cancer and why they should be evaluated during preclinical and clinical development.
Pharmacokinetic and Pharmacodynamic Aspects of Focal and Targeted Delivery of Drugs
The major pharmacokinetic and pharmacodynamic parameters that govern the clinical effectiveness of systemically and focally administered DDSs are presented, and the ways to control the drug/DDSs disposition and the efficiency of the pharmacological responses are discussed.
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
This report summarizes the workshop discussions on key issues of the EPR effect and major gaps that need to be addressed to effectively advance nanoparticle-based drug delivery.
Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT)
In mice bearing flank tumor xenografts, SMs distribute into tumor more efficiently than CMAs, and a novel PK metric entitled relative distribution over time (RDI-OT), which measures efficiency of delivery is indicated.
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.


Pharmacokinetics and biodistribution of nanoparticles.
Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The
Concept and clinical evaluation of carrier-mediated anticancer agents.
This review focuses on the concepts and clinical evaluation of carrier-mediated anticancer agents that are administered i.v. or orally, and the factors affecting the pharmacokinetic and pharmacodynamic variability of these agents remain unclear.
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
There are many potential barriers to the effective delivery of a drug in its active form to solid tumors. Most small-molecule chemotherapeutic agents have a large volume of distribution on i.v.
Nanoparticle therapeutics: a personal perspective.
  • S. McNeil
  • Biology
    Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
  • 2009
Some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics are reviewed.
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
  • W. Zamboni
  • Chemistry, Biology
    Clinical Cancer Research
  • 2005
Pegylated-STEALTH liposomal doxorubicin (Doxil, Caelyx) was the firstliposomal to be isolated from liposomes and used in drug discovery and characterization.
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
Age, gender, and monocyte counts appear to correlate with PLD clearance, and these effects on the pharmacokinetics of PLD may be an approach for personalizing PLD therapy and may affect other pegylated liposomes and nanoparticle agents.
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
The rationale for selecting optimal strategies of liposomal drug formulations with respect to drug encapsulation, retention, and release, and how these strategies can be applied to maximize therapeutic benefit in vivo are described.
The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents.
This data indicates that Peglyated liposomal anticancer agents are nanoparticles that may improve antitumor efficacy by enhancing tumor drug delivery while limiting exposure in normal tissues.
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD], was developed to enhance the safety and efficacy of conventional doxorbicin and has potential applications to treat a variety of cancers.
Nanomedicines for overcoming biological barriers.
  • M. Alonso
  • Biology
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • 2004